Review Article
Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma
Table 3
Autologous hematopoietic cell transplantation for follicular lymphoma that has undergone histological transformation to large cell lymphoma.
| | Author (year) | Number of patients | Age (range) | Conditioning regimen | TRM | PFS | OS | Comments |
| | Friedberg et al. [56] (1999) | 21 | 44
(29–58) | TBI/CY | NA | 46%
(5 years) | 58%
(5 years) | All had minimal disease state. Purged autograft used. |
| | Chen et al. [58] (2001) | 25a | 48
(36–64) | Mel/TBI/VP | 28% | 36%
(5 years) | 37%
(5 years) | All had chemosensitive disease. |
| | Williams et al. [57, 61] (2001) | 50 | 40
(26–52) | Various regimens | 8%
(100 days) | 30%
(5 years) | 51%
(5 years) | 100% had chemo-sensitive disease. High LDH led to poor outcomes. |
| | Hamadani et al. [59] (2008) | 24 | 56
(47–68) | BU/CY
BCNU based | 8%
(100 days) | 40%
(3 years) | 52%
(3 years) | 17% had bulky disease and no purged autografts used. |
| | Eide et al. [60] (2011) | 30b | 55
(31–65) | BEAM | NA | 32%
(5 years) | 47%
(5 years) | The only prospective trial. All 30 had chemosensitive disease. |
|
|
Abbreviations: TBI: total body irradiation; CY: cyclophosphamide; Mel: melphalan; VP: etoposide; BU: busulfan; BCNU: carmustine; TRM: treatment-related mortality; PFS: progression-free survival; OS: overall survival; LDH: lactate dehydrogenase; BEAM: BCNU, etoposide, cytarabine, melphalan.
aOf the 35 patients in the sample, only 25 had true histological transformation to diffuse large B-cell lymphoma. bOf the 47 patients enrolled, only 30 underwent autologous hematopoietic cell transplantation.
|
